The Lynx Group

Rüdiger Hehlmann, MD, PhD


Authored Items

Implementing the Promise of Personalized Cancer Care

June 2012, Vol 1, No 2 - Uncategorized

To receive credit, complete the posttest at www.mlicme.org/P11077.html.   Until recently, cancer treatment relied solely on histologic diagnosis for determining systemic therapy. Aside from considerations related to a patient’s underlying comorbidities and performance status, there was minimal deviation from an organ-of-origin–based treatment strategy. This relatively primitive understanding of malignancy failed [ Read More ]

Sign me up!